Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 10:23 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1009–1032 of 6,313 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Advanced therapy Clear all

Conditions: Pancreatic Cancer Non-resectable
Interventions: Pamrevlumab + Gemcitabine + Nab-paclitaxel or Pamrevlumab + FOLFIRINOX, Placebo + Gemcitabine + Nab-paclitaxel or Placebo + FOLFIRINOX; Drug
Lead sponsor: Kyntra Bio; Industry
Eligibility: 18 Years and older
Enrollment: 284 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 32
States / cities: Phoenix, Arizona • La Jolla, California • Los Angeles, California + 28 more

Conditions: Hepatocellular Carcinoma
Interventions: AZD5851; Biological
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 16
States / cities: Phoenix, Arizona • Duarte, California • Los Angeles, California + 13 more

Conditions: Solid Cancers
Interventions: GDC-0941; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 3
States / cities: Scottsdale, Arizona • Boston, Massachusetts • Detroit, Michigan

Conditions: Head and Neck Cancer, Hearing Loss, Tinnitus, Dysphagia
Interventions: TIMELY REHAB; Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 89 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2030
U.S. locations: 3
States / cities: Durham, North Carolina • Portland, Oregon • Madison, Wisconsin

Conditions: Solid Tumor, Sarcoma, Leiomyosarcoma, Dedifferentiated Liposarcoma
Interventions: STC-15 in combination with toripalimab, STC-15 monotherapy; Drug
Lead sponsor: STORM Therapeutics LTD; Industry
Eligibility: 18 Years and older
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 14
States / cities: San Francisco, California • Miami, Florida • Boston, Massachusetts + 9 more

Conditions: Melanoma
Interventions: TAK-580, TAK-202, vedolizumab, nivolumab, ipilimumab; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 14
States / cities: Tucson, Arizona • Los Angeles, California • San Francisco, California + 10 more

Conditions: Colorectal Cancer, Breast Cancer, Lung Cancer, Pancreatic Cancer, Colon Cancer
Interventions: AVX701; Biological
Lead sponsor: AlphaVax, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Advanced Malignant Solid Neoplasm
Interventions: Dinaciclib, Veliparib; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2027
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Non-Small-Cell Lung Cancer Metastatic, Non-Small Cell Carcinoma of Lung, TNM Stage 4, Nonsmall Cell Lung Cancer, Non Small Cell Lung Cancer Recurrent
Interventions: Nivolumab, nab-paclitaxel; Drug
Lead sponsor: Alliance Foundation Trials, LLC.; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 4
States / cities: Edgewood, Kentucky • Saint Louis Park, Minnesota • St Louis, Missouri + 1 more

Conditions: Neoplasms, Cancer of the Ovary
Interventions: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 218 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Head and Neck Squamous Cell Carcinoma
Interventions: Capecitabine, Docetaxel, Quality-of-Life Assessment, Questionnaire Administration; Drug · Other
Lead sponsor: University of Nebraska; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 3
States / cities: Norfolk, Nebraska • Omaha, Nebraska

Conditions: Adenocarcinoma
Interventions: ING-1(heMAb); Drug
Lead sponsor: XOMA (US) LLC; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Cryptosporidiosis, HIV Infections
Interventions: Paromomycin sulfate; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1996
U.S. locations: 14
States / cities: Los Angeles, California • Miami, Florida • Chicago, Illinois + 7 more

Conditions: Melanoma
Interventions: Mature dendritic cell (DC) vaccine, Cyclophosphamide 300mg/m^2, Pembrolizumab; Biological · Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Esophageal Cancer
Interventions: cisplatin, docetaxel, irinotecan hydrochloride, radiation therapy; Drug · Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 1
States / cities: New York, New York

Conditions: Advanced/Metastatic Solid Tumors or Lymphomas
Interventions: ADU-S100, ipilimumab; Drug · Biological
Lead sponsor: Chinook Therapeutics, Inc. (formerly Aduro); Industry
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 7
States / cities: Aurora, Colorado • Chicago, Illinois • Baltimore, Maryland + 4 more

Conditions: Cancers With HER2 Expression
Interventions: BAY2701439; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 4
States / cities: Baltimore, Maryland • St Louis, Missouri • New York, New York + 1 more

Conditions: Tumor, Solid
Interventions: BDB001 (EIK1001), Atezolizumab; Drug
Lead sponsor: Eikon Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 5
States / cities: Los Angeles, California • Sarasota, Florida • Nashville, Tennessee + 1 more

Conditions: Cirrhosis, Liver
Interventions: Ceftriaxone, Normal saline; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Advanced Solid Tumors Cancer
Interventions: ABBV-CLS-579, PD-1 inhibitor, VEGFR TKI; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 5
States / cities: Springdale, Arkansas • New Haven, Connecticut • Fort Wayne, Indiana + 2 more

Conditions: Leukemia
Interventions: MEK 162; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Advanced Cancer
Interventions: FDG; Radiation
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 21 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Transitional Cell Carcinoma, Bladder Carcinoma, Urothelial Carcinoma
Interventions: Everolimus, Paclitaxel; Drug
Lead sponsor: Matthew Galsky; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 11
States / cities: Birmingham, Alabama • Chicago, Illinois • Bloomington, Indiana + 7 more

Conditions: Liposarcoma, Leiomyosarcoma
Interventions: Yondelis, Dexamethasone; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years and older
Enrollment: 271 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 20
States / cities: Los Angeles, California • Aurora, Colorado • Coeur d'Alene, Idaho + 17 more

Search by objective public record fields.

Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Participants With Locally Advanced, Unresectable Pancreatic Cancer

A Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular Carcinoma

A Study of GDC-0941 in Participants With Locally Advanced or Metastatic Solid Tumors for Which Standard Therapy Either Does Not Exist or Has Proven Ineffective or Intolerable

Maximizing Quality of Life After Cancer Through Rehabilitation

STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas

Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma

A Phase I/II Study With CEA(6D) VRP Vaccine in Patients With Advanced or Metastatic CEA-Expressing Malignancies

Veliparib and Dinaciclib in Treating Patients With Advanced Solid Tumors

A Study of Nivolumab +/- Nab-paclitaxel in Non-small Cell Lung Cancer

Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer

Docetaxel and Capecitabine With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Phase I Study of a Monoclonal Antibody for Treatment of Advanced Adenocarcinomas

A Double-Blind, Placebo-Controlled Trial of Paromomycin for Treatment of Cryptosporidiosis in Patients With Advanced HIV Disease and CD4 Counts Under 150 Cells/mm3

Dendritic Cell Vaccination in Patients With Advanced Melanoma

Irinotecan, Radiation Therapy, and Docetaxel With or Without Cisplatin in Treating Patients With Locally Advanced Esophageal Cancer

Safety and Efficacy of MIW815 (ADU-S100) +/- Ipilimumab in Patients With Advanced/Metastatic Solid Tumors or Lymphomas

A First in Human Study of BAY2701439 to Look at Safety, How the Body Absorbs, Distributes and Excretes the Drug, and How Well the Drug Works in Participants With Advanced Cancer Expressing the HER2 Protein

BDB001-102: Open Label Dose Escalation of BDB001 in Combination w Atezolizumab

Prophylactic Antibiotics in Admitted Cirrhotics

First In Human Study With ABBV-CLS-579 When Given Alone and In Combination In Participants With Locally Advanced Or Metastatic Tumors

MEK Inhibitor 162 Relapsed and/or Refractory Acute Myeloid Leukemia (AML) and Poor Prognosis, Not Suitable for or Unwilling to Receive Standard Therapy

A Pilot Study Treatment of Malignant Tumors Using [18F] Fluorodeoxyglucose (FDG)

First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma

A Study to Assess Treatment With 2 Different Dosing Schedules of Trabectidin Administered to Patients With Advanced Cancer